# Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

> **NCT05406206** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 27 (estimated)

## Conditions studied

- Advanced Colorectal Carcinoma
- Liver Metastasis Colon Cancer

## Interventions

- **DRUG:** Fruquintinib
- **PROCEDURE:** Hepatic Arterial Infusion Chemotherapy

## Key facts

- **NCT ID:** NCT05406206
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-25
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406206, "Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05406206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*